Tag: drug eluting stents

1. In comparison to everolimus-eluting metallic stents (EESs), bioresorbable vascular scaffolds (BVSs) increased the chances for thrombotic events at both ...

1. Device thrombosis occurred at a higher rate in patients undergoing percutaneous coronary intervention (PCI) utilizing a bioabsorbable scaffold compared ...

1. A prediction model for assessing the harm and benefit of long-term dual antiplatelet therapy after percutaneous coronary intervention (PCI) ...

1. After 12 months of dual antiplatelet therapy in patients who received drug eluting stents (DES), patients who continued on ...

1. From a systematic review, longer duration dual-antiplatelet therapy was associated with a decreased risk of myocardial infarction in patients ...

In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. 6- ...

In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Twelve ...

1. After 12 months of dual antiplatelet therapy, patients who continued on a thienopyridine in addition to aspirin for 18 ...

1. In the BIOSCIENCE trial, a novel biodegradable polymer sirolimus-eluting stent (Orsiro) was non-inferior to the durable polymer everolimus-eluting stent ...

Image: PD  1. The major predictors of major adverse cardiac events in non-cardiac surgery in the two years following cardiac ...